Page 25 - 51 the significance--29.2_opt

References:

1. The American Association of Clinical Endocrinologists Medical Guidelines for the
Management of Diabetes Mellitus: the AACE system of intensive diabetes self-
management--2000 update. Endocr Pract 2000;6(1):43-84.
2. Matthaei S, Stumvoll M, Kellerer M, Haring HU. Pathophysiology and pharmacological
treatment of insulin resistance. Endocrine reviews 2000;21(6):585-618.
3. Wajchenberg BL. beta-cell failure in diabetes and preservation by clinical treatment.
Endocrine reviews 2007;28(2):187-218.
4. WHO. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia:
WHO, 2006.
5. ADA. Standards of medical care in diabetes--2010. Diabetes care 2010;33 Suppl 1:
S11-61.
6. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, et al. Impaired
fasting glucose and impaired glucose tolerance: implications for care. Diabetes
care 2007;30(3):753-9.
7. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up report
on the diagnosis of diabetes mellitus. Diabetes care 2003;26(11):3160-7.
8. Mellitus ECotDaCoD. Report of the Expert Committee on the Diagnosis and Classifi-
cation of Diabetes Mellitus. Diabetes care 1997;20(7):1183-97.
9. Jung CY, Lee W. Glucose transporters and insulin action: some insights into diabetes
management. Archives of pharmacal research 1999;22(4):329-34.
10. Shepherd PR, Kahn BB. Glucose transporters and insulin action--implications
for insulin resistance and diabetes mellitus. The New England journal of medicine
1999;341(4):248-57.
11. Benardot D. Advanced Sports Nutrition. Champaign: Human Kinetics, 2006.
12. Nussey S, Whitehead S. The Endocrine Pancreas Endocrinology: an integrated ap-
proach. Oxford: BIOS Scientific Publishers Ltd 2001.
13. Ratnayake WM, Galli C. Fat and fatty acid terminology, methods of analysis and
fat digestion and metabolism: a background review paper. Annals of nutrition &
metabolism 2009;55(1-3):8-43.
14. Williams G, Pickup JC. Handbook of Diabetes, 3rd Edition: Wiley-Blackwell, 2004.
15. DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion
responsible for NIDDM. Diabetes 1988;37(6):667-87.
16. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. The Medical clinics of North
America 2004;88(4):787-835, ix.
17. Olatunbosun S, Dagogo-Jack S. Insulin resistance: eMedicine, WebMD, 2009.
18. Rhodes CJ, White MF. Molecular insights into insulin action and secretion. European
journal of clinical investigation 2002;32 Suppl 3:3-13.
19. Youssef W, McCullough AJ. Diabetes mellitus, obesity, and hepatic steatosis. Seminars
in gastrointestinal disease 2002;13(1):17-30.
20. Wellcome Trust. How does obesity cause ill-health?: Wellcome Trust, 2009.
21. FEND. Diabetes. The policy puzzle: Is Europe making progress. , 2008.
22. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and
increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52(1):
102-10.
23. Drews G, Krippeit-Drews P, Dufer M. Oxidative stress and beta-cell dysfunction.
Pflugers Arch 2010;460(4):703-18.
24. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining
their role in the development of insulin resistance and beta-cell dysfunction.
European journal of clinical investigation 2002;32 Suppl 3:14-23.
25. Kaiser N, Leibowitz G, Nesher R. Glucotoxicity and beta-cell failure in type 2 diabetes
mellitus. J Pediatr Endocrinol Metab 2003;16(1):5-22.
26. International Diabetes Federation. IDF Diabetes Atlas, 4th edition, 2009.
27. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr
before clinical diagnosis. Diabetes care 1992;15(7):815-9.
28. Votey S, Peters A. Diabetes, Type 2 - A Review: Web MD, 2010.
29. Hewitt Associates LLC. Trends in HR and Employee Benefits: Chronic disease analysis -
diabetes trends, 2009.

25